Nautilus to bring proteomics platform to market

By The Science Advisory Board staff writers

May 22, 2020 -- Nautilus Biotechnology announced that it has raised $76 million to develop a single-molecule sensitivity proteomics platform. The funding efforts were led by Vulcan Capital, an investment firm founded by Microsoft co-founder Paul Allen.

The company will use the funds to develop technologies that enable a deeper, richer understanding of proteins and to expand scientific and engineering staff across a wide variety of levels and disciplines. The proprietary proteomics platform will bring increased resolution of the human proteome, according to Nautilus.

In addition to Vulcan, Perceptive Advisors, Bezos Expeditions, and Defy Partners were new investors in the series B offering. Previous investors included AME Cloud Ventures, Andreessen Horowitz, Bolt, and Madrona Venture Group.

Vividion, Roche partner for small-molecule drug discovery
Biotechnology company Vividion Therapeutics has signed an exclusive worldwide option and license agreement with Roche.
Proteomics provides insights into SARS-CoV-2 infection, potential therapies
Scientists tested a series of compounds for blocking the replication of SARS-CoV-2 using a novel proteomics approach. The method, which helped identify...
Chemists develop method to identify protein neighbors
A new technology called µMap uses photocatalysts, molecules that spur a chemical reaction when activated by light, to identify spatial relationships...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter